{"product_id":"dexcom-pestle-analysis","title":"DexCom PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how regulatory shifts, reimbursement trends, and rapid tech advances are reshaping DexCom’s growth trajectory—our PESTLE distills these forces into clear, actionable insights for investors and strategists; buy the full analysis to access the detailed risks, opportunities, and strategic recommendations you need to act confidently.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare and Medicaid reimbursement expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpexpansion of medicare coverage to non-insulin using type patients by late raised dexcom addressable u.s. market an estimated with cms pilots showing cgm cuts in er visits up and annual per-patient cost savings framing as preventive care shifts policy toward long-term stabilizing recurring revenue reducing payer churn. greater public accelerates adoption among lower-income demographics supporting volume growth pricing leverage.\u003e\n\u003c\/pexpansion\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational trade and tariff policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOngoing trade tensions between the US and major manufacturing hubs, notably tariffs on Chinese electronics rising to as high as 25% during 2024 policy adjustments, increase component costs for DexCom’s sensors and risk raising COGS by an estimated 3–5% per unit.\u003c\/p\u003e\n\u003cp\u003eShifts in tariff structures force DexCom to keep a flexible global supply chain—70% of components sourced APAC—so re-shoring or dual-sourcing is required to protect FY2024 gross margin (reported 65.1%) from further compression.\u003c\/p\u003e\n\u003cp\u003ePolitical stability in target expansion regions—EMEA and LATAM contributed ~28% of 2024 revenue—remains critical for capital allocation and multi-year operational planning to avoid supply disruptions and regulatory delays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational healthcare infrastructure reforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpmany european and asian governments shifting to value-based care tie reimbursements outcomes oecd data shows pilots covering over of diabetes programs in select eu countries. are increasing subsidies for digital health investment reached tools that cut readmissions studies report cgm use lowers diabetes-related by up dexcom with revenue global adoption growth yoy can leverage its continuous glucose demonstrate outcome improvements secure reimbursement contracts under these reforms.\u003e\n\u003c\/pmany\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic health initiatives and funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment focus on obesity has increased funding for diabetes awareness and early intervention; WHO estimates adult obesity rose to 13% globally by 2016 and many governments boosted prevention budgets—US CDC prevention funding reached about $1.4 billion in 2024 for chronic disease programs.\u003c\/p\u003e\n\u003cp\u003eInitiatives promote wearables for metabolic monitoring, with global wearable medical device market at $35.4 billion in 2024, creating adoption pathways for Dexcom’s non-diagnostic glucose monitors.\u003c\/p\u003e\n\u003cp\u003ePolitical backing for preventive tech creates favorable regulatory and reimbursement environments, aiding Dexcom’s market expansion and product positioning.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWHO: global adult obesity ~13% (2016 baseline) influencing policy\u003c\/li\u003e\n\u003cli\u003eUS CDC chronic disease prevention funding ~$1.4B (2024)\u003c\/li\u003e\n\u003cli\u003eWearable medical device market ~$35.4B (2024)\u003c\/li\u003e\n\u003cli\u003ePolicy support boosts Dexcom’s non-diagnostic monitor adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory harmonization across borders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory harmonization by bodies like the EU MDR alignment efforts and ICH guidance has shortened Dexcom’s time-to-market, supporting 2024 revenue growth where international sales contributed about 28% of total $3.9B revenue.\u003c\/p\u003e\n\u003cp\u003eSynchronization of safety standards enables coordinated global rollouts of Continuous Glucose Monitoring (CGM) updates, lowering compliance costs and accelerating adoption in key markets.\u003c\/p\u003e\n\u003cp\u003eConversely, rising protectionist regulatory moves in some emerging markets could fragment approvals and slow expansion, risking margin pressure and delayed incremental international revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHarmonization speeds launches; international sales = ~28% of 2024 revenue\u003c\/li\u003e\n\u003cli\u003eSynchronized standards reduce compliance costs and accelerate CGM updates\u003c\/li\u003e\n\u003cli\u003eIsolationist rules in emerging markets could delay rollouts and pressure margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicaid expansion and VBR fuel Dexcom growth; tariffs and APAC sourcing pose COGS risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExpanded Medicare\/Medicaid coverage (~+20–25% US addressable market by 2025) and value-based reimbursement adoption (EU pilots \u0026gt;30%) boost Dexcom’s recurring revenue and adoption; trade tariffs (up to 25% in 2024) and 70% APAC sourcing risk 3–5% COGS pressure; international sales ~28% of 2024 revenue; wearable market ~$35.4B (2024); CDC prevention funding ~$1.4B (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS addressable ↑\u003c\/td\u003e\n\u003ctd\u003e+20–25% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariff risk\u003c\/td\u003e\n\u003ctd\u003eup to 25% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPAC sourcing\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl revenue\u003c\/td\u003e\n\u003ctd\u003e~28% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWearable market\u003c\/td\u003e\n\u003ctd\u003e$35.4B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDC prevention\u003c\/td\u003e\n\u003ctd\u003e$1.4B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental forces uniquely impact DexCom across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and forward-looking insights to identify risks and opportunities for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses DexCom's PESTLE into a concise, easily shareable brief that highlights regulatory, technological, and market risks for fast alignment in meetings and slide decks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary pressures on manufacturing costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFluctuations in raw material and specialized electronics costs have pressured margins for G7 and next‑gen sensors; semiconductor spot prices rose ~18% in 2024 while specialty polymers increased ~12%, squeezing component cost per sensor by an estimated 6–9% year‑over‑year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDisposable income and consumer spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs Dexcom targets Type 2 and wellness consumers, out-of-pocket affordability drives adoption; in the US 2023 median household disposable income was about $74,000 while 2024 consumer spending rose 2.7%, affecting willingness to pay for sensors not fully covered by insurance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange rate volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs a global entity, Dexcom is exposed to USD volatility versus the euro, yen and other currencies; in FY2025 roughly 28% of net revenue was non‑U.S., so a 5% dollar strength could cut reported international revenue by about 1.4%. Significant exchange shifts affect foreign pricing competitiveness and margins, especially in Europe and Japan where devices and sensors face local reimbursement pressures. Management reported active hedging covering a portion of forecasted cash flows in 2024–2025, but prolonged economic instability in key regions remains a material risk to revenue predictability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth insurance premium and coverage trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe financial health of private insurers shapes coverage and patient co-pays for DexCom CGMs; in 2024 US private insurer medical loss ratios averaged ~86%, affecting willingness to expand benefits and influencing co-pay levels.\u003c\/p\u003e\n\u003cp\u003eGrowth in high-deductible health plans—64% of covered workers had an HDHP in 2023—can delay CGM starts as patients face upfront costs, while insurers noting reduced diabetes complications and lower total claims (studies show CGM can cut hospitalization rates by ~30%) may reduce barriers and co-pays.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInsurer MLR ~86% (2024) impacts benefit expansion\u003c\/li\u003e\n\u003cli\u003e64% of workers in HDHPs (2023) raises upfront cost burden\u003c\/li\u003e\n\u003cli\u003eCGM-linked ~30% lower hospitalizations supports broader coverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetitive pricing and market saturation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDexCom faces downward ASP pressure as Abbott’s FreeStyle Libre and lower-cost entrants push CGM average selling prices; Libre’s ASP estimates fell ~10–15% in several markets in 2024, forcing price competition.\u003c\/p\u003e\n\u003cp\u003eTo sustain a premium, DexCom must keep innovating (e.g., G7 launch benefits) or scale into lower-margin, high-volume segments; operating leverage matters as CGM penetration nears 10–15% of people with diabetes in developed markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eASP decline pressure: ~10–15% observed vs 2023–24\u003c\/li\u003e\n\u003cli\u003eNeed for innovation: G7 timing and differentiation\u003c\/li\u003e\n\u003cli\u003eScale importance: margins tied to operating leverage as market commoditizes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising component costs and Libre price cuts squeeze sensor margins, FX trims revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising component costs (semiconductors +18% and specialty polymers +12% in 2024) squeezed sensor costs ~6–9% YoY; 28% of revenue non‑U.S. in FY2025 means 5% USD strength cuts reported international revenue ~1.4%; US HDHP prevalence 64% (2023) raises upfront patient cost while insurer MLR ~86% (2024) limits benefit expansion; Libre ASPs down ~10–15% in 2024 pressuring Dexcom pricing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSemiconductor spot price (2024)\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty polymers (2024)\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSensor cost impact\u003c\/td\u003e\n\u003ctd\u003e+6–9% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon‑US revenue (FY2025)\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD 5% strength effect\u003c\/td\u003e\n\u003ctd\u003e≈‑1.4% intl rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHDHP prevalence (2023)\u003c\/td\u003e\n\u003ctd\u003e64%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInsurer MLR (2024)\u003c\/td\u003e\n\u003ctd\u003e~86%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLibre ASP change (2024)\u003c\/td\u003e\n\u003ctd\u003e‑10–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eDexCom PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact DexCom PESTLE document you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic analysis and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751390589305,"sku":"dexcom-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/dexcom-pestle-analysis.png?v=1772230811","url":"https:\/\/growthsharematrix.com\/products\/dexcom-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}